Latest filing published 11 Jun 2026 for KalVista Pharmaceuticals, Inc.. Read the official filing
Paul K. Audhya discloses dealings in KalVista Pharmaceuticals, Inc. to SEC (Form 4). We count 37 filings; the first trade dates from 17 August 2022 and the latest from 11 June 2026.
The open-market record consists of 9 sales worth €473k, with no purchase. The rest of the record consists of 27 option exercises. So far in 2026, the count stands at no purchases and 3 sales.
On 11 June 2026 came the latest disclosure, a transaction in KalVista Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 37 declarations